Table 2. Tolerability for Repeated Dose Administration In Vivo (Mouse)a.
| prodrug | studies | dose (mg/kg) | remarks |
|---|---|---|---|
| SS60-CBI-AZI | PK, MTD | 0.3–1 | adverse effects |
| SeS60-CBI-AZI | MTD | 0.3–1 | adverse effects |
| O56-CBI-AZI | MTD | 1 | |
| P-SS60-CBI-AZI | MTD, efficacy | 3 | well tolerated |
| P-SS60-CBI-TMI | MTD, efficacy | 3 | well tolerated |
| P-SS66C-CBI-TMI | MTD, efficacy | 3 | well tolerated |
| Me-SS66C-CBI-TMI | MTD, efficacy | 3 | well tolerated |
| Me-SS66T-CBI-TMI | MTD, efficacy | 3 | well tolerated |
| P-CC60-CBI-TMI | MTD, efficacy | 3 | well tolerated |
a
The table summarizes dosages that are well-tolerated under weekly or twice-weekly administration, as tested in multiple study settings (PK: pharmacokinetics; MTD: maximum tolerated dose).